The university was founded as Emory College in 1836 in Oxford, Georgia by a small group of Methodists and was named in honor of Methodist bishop John Emory. A land-grant by Asa Candler in 1915, then president of The Coca-Cola Company, allowed the small college to move to metropolitan Atlanta and become rechartered as Emory University. The university’s mission statement is “to create, preserve, teach, and apply knowledge in the service of humanity.”
The university has nearly 3,000 faculty members; awards and honors recognizing Emory faculty include the Nobel Prize, the Pulitzer Prize, National Humanities Medal, Guggenheim Fellowship, Fulbright Fellowship, and membership in the American Academy of Arts & Sciences and the National Academy of Sciences. Emory is ranked 20th among national universities in U.S. News & World Report ‘s 2014 rankings.
The university has nine academic divisions: Emory College of Arts and Sciences, Oxford College, Goizueta Business School, Laney Graduate School, School of Law, School of Medicine, Nell Hodgson Woodruff School of Nursing, Rollins School of Public Health, and the Candler School of Theology.
The university has more than two million square feet of building space certified by the Leadership in Energy and Environmental Design program and has a commitment to having three-quarters of the food served on campus come from local or sustainable sources by 2015. The university holds the distinction of having one of the largest inventories by square footage of LEED-certified building space among campuses in America.
Emory University research articles from Innovation Toronto
- UGA’s Regenerative Bioscience Center collaborates in development of brain-friendly interfaces – August 10, 2015
- Tiny Bottles and Melting Corks: Temperature Regulates a New Delivery System for Drugs and Fragrances
- University nonprofit poised to bridge ‘Valley of Death’ and spur drug development
- Steering stem cells with magnets
- For Solazyme, a Side Trip on the Way to Clean Fuel
- Biomaterial Shows Promise for Type 1 Diabetes Treatment
- Robots able to reach through clutter with whole-arm tactile sensing
- Brain Scans Reveal What Dogs Are Thinking
- Online Gamers Achieve First Crowd-Sourced Redesign of Protein
- Paul Root Wolpe: It’s time to question bio-engineering
- Finding a Medical “Silver Bullet” to Disable Many of the World’s Deadliest Viruses
- Breakthrough in quest for solar hydrogen production
Scientists are making the case that a vaccine against rhinoviruses, the predominant cause of the common cold, is achievable.
The quest for a vaccine against rhinoviruses may have seemed quixotic, because there are more than 100 varieties circulating around the world. Even so, the immune system can handle the challenge, researchers from Emory University School of Medicine and Children’s Healthcare of Atlanta say.
Vaccines that combine dozens of varieties of rhinovirus at once are effective in stimulating antiviral antibodies in mice and monkeys, the researchers report in Nature Communications. The paper was also posted on Biorxiv before publication.
“We think that creating a vaccine for the common cold can be reduced to technical challenges related to manufacturing,” says Martin Moore, PhD, associate professor of pediatrics at Emory University School of Medicine.
Rhinoviruses are the most common cause of the common cold; other viruses such as respiratory syncytial virus, parainfluenza virus and adenoviruses can cause them too. Rhinoviruses also exacerbate asthma attacks. Although they come in many varieties, rhinoviruses do not drift to the same degree that influenza viruses do, Moore says.
Researchers showed in the 1960s that it was possible to vaccinate people against one variety of rhinovirus and prevent them from getting sick when challenged with samples of the same virus. The trouble was the sheer diversity of rhinoviruses – or that’s how it appeared at the time.
“It’s surprising that nobody tried such a simple solution over the last 50 years. We just took 50 types of rhinovirus and mixed them together into our vaccine, and made sure we had enough of each one,” Moore says. “If we make a vaccine with 50 or 100 variants, it’s the same amount of total protein in a single dose of vaccine. The variants are like a bunch of slightly different Christmas ornaments, not really like 50 totally different vaccines mixed.”
A mixture of 25 types of inactivated rhinovirus can stimulate neutralizing antibodies against all 25 in mice, and a mixture of 50 types can do the same thing in rhesus macaques. In this paper, antibodies generated in response to the vaccine were tested for their ability to prevent the virus from infecting human cells in culture. However, the vaccines were not tested for their ability to stop animals from getting sick.
“There are no good animal models of rhinovirus replication,” Moore says. “The next step would be human challenge models with volunteers, which are feasible because the virus is not very pathogenic.”
Emory has optioned the vaccine technology to a startup company, Meissa Vaccines, Inc., which is pursuing a product development plan with support from the National Institute of Allergy and Infectious Diseases’ vaccine manufacturing services.
Learn more: Vaccine vs many common cold viruses achievable